Journals / The Anatolian Journal of Cardiology / 2015 / Cilt: 15 - Sayı: 2

Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention

Pages
125–131
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Single oral dose of nicorandil (10 mg, 20 mg) 2 hours before the PCI procedure could decrease the incidence of peri-procedure myocardial injury and PCI-related myocardial infarction. (Anatolian J Cardiol 2015; 15: 125-31)

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Nicorandil, an opener of ATP-sensitive K+ channels, was used to treat angina in patients with coronary artery disease.
📊
Key Findings & Data:In this study, we aim to investigate the cardioprotective effects of single oral dose of nicorandil in patients undergoing selective percutaneous coronary intervention (PCI).
💡
Conclusion & Impact:Conclusion: Single oral dose of nicorandil (10 mg, 20 mg) 2 hours before the PCI procedure could decrease the incidence of peri-procedure myocardial injury and PCI-related myocardial infarction. (Anatolian J Cardiol 2015; 15: 125-31)
🔬Design:Research Article
📍Scope:2011 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Nicorandil, an opener of ATP-sensitive K+ channels, was used to treat angina in patients with coronary artery disease. In this study, we aim to investigate the cardioprotective effects of single oral dose of nicorandil in patients undergoing selective percutaneous coronary intervention (PCI). Methods: One hundred and thirty-eight patients with acute coronary syndrome undergoing PCI from July 2011 to October 2012 were randomly divided into control group (group 1, n=47), 10 mg oral nicorandil group (group 2, n=45), and 20 mg oral nicorandil group (group 3, n=46) about 2 hours before procedure, respectively. Cardiac troponin I (cTnI) levels were determined at 20 ~ 24 hours after PCI. Results: There was a significant difference in the rate of any cTnI elevation among the three groups (group 1: 36.17%, group 2: 20.00%, group 3: 15.22%, p=0.0176). With respect to the frequency of cTnI elevation ≥3 and 5× the upper limit of normal (ULN), there also had statistical difference among the three groups (17.02% in group 1, 8.89% in group 2, and 4.35% in group 3, respectively for cTnI elevation ≥3× ULN, p=0.0428; 12.77% in group 1, 6.67% in group 2, and 2.17% in group 3, respectively, for cTnI elevation ≥5× ULN, p=0.0487). Logistic regression analysis showed that LVEF (OR=0.915, 95% CI=0.853-0.981) and the use of nicorandil (OR=0.516, 95% CI=0.267-0.996) before PCI were independent protective factors of myocardial injury. Conclusion: Single oral dose of nicorandil (10 mg, 20 mg) 2 hours before the PCI procedure could decrease the incidence of peri-procedure myocardial injury and PCI-related myocardial infarction. (Anatolian J Cardiol 2015; 15: 125-31)

🔖

Cite This Article

YANG, J., ZHANG, J., CUİ, W., LİU, F., XİE, R., YANG, X., GU, G., ZHENG, H., LU, J., YANG, X., ZHANG, G., WANG, Q., GENG, X. (2015). Cardioprotective effects of single oral dose of nicorandil before selective percutaneous coronary intervention. The Anatolian Journal of Cardiology, Cilt: 15 - Sayı: 2, 125–131. https://ajindex.com/articles/366147

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Willerson JT, Watson JT, Hutton I, Templeton GH, Fixler DE. Reduced myocardial reflow and increased coronary vascular resistance following prolonged myocardial ischemia in the dog. Circ Res 1975
  2. [CrossRef] 2. Willerson JT, Scales F, Mukherjee A, Platt M, Templeton GH, Fink GS, et al. Abnormal myocardial fluid retention as an early manifestation of ischemic injury. Am J Pathol 1977
  3. Simoons ML, van den Brand M, Lincoff M, Harrington R, van der Wieken R, Vahanian A, et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 1999
  4. [CrossRef] 4. Abdelmeguid AE, Topol EJ, Whitlow PL, Sapp SK, Ellis SG. Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. Circulation 1996
  5. [CrossRef] 5. Brener SJ, Ellis SG, Schneider J, Topol EJ. Frequency and longterm impact of myonecrosis after coronary stenting. Eur Heart J 2002
  6. [CrossRef] 6. Novack V, Pencina M, Cohen DJ, Kleiman NS, Yen CH, Saucedo JF, et al. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Arch Intern Med 2012
  7. [CrossRef] 7. Tardiff BE, Califf RM, Tcheng JE, Lincoff AM, Sigmon KN, Harrington RA, et al. Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. J Am Coll Cardiol 1999
  8. [CrossRef] 8. Katus HA, Remppis A, Neumann FJ, Scheffold T, Diederich KW, Vinar G, et al. Diagnostic efficiency of troponin T measurements in acute myocardial infarction. Circulation 1991
  9. [CrossRef] 9. Rottbauer W, Greten T, Muller-Bardorff M, Remppis A, Zehelein J, Grunig E, et al. Troponin T: a diagnostic marker for myocardial infarction and minor cardiac cell damage. Eur Heart J 1996
  10. [CrossRef] 10. Saadeddin SM, Habbab MA, Sobki SH, Ferns GA. Detection of minor myocardial injury after successful percutaneous transluminal coronary angioplasty with or without stenting. Med Sci Monit 2000
  11. Zemanek D, Branny M, Martinkovicova L, Hajek P, Maly M, Tesar D, et al. Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. Int J Cardiol 2013
  12. [CrossRef] 12. Li Q, Deng SB, Xia S, Du JL, She Q. Impact of intensive statin use on the level of inflammation and pla